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http://djournal homepage: www.elsevier.com/locate/jboEditorialRANK/RANKL pathway in cancer: Biological activity beyond bone?Roughly 15 years have gone by since the identiﬁcation of the
main characters involved in the interplay of the RANK–RANKL
system. This gave rise to the race for elucidating their biological
role [1]. In those years, in vivo silencing experiments for both
Receptor Activator of Nuclear Factor k B (RANK) and its ligand
RANKL showed that RANK, and RANKL negative mutant mice
exhibit severe osteopetrosis due to a complete lack in osteoclast
activation.
RANKL is produced mainly by the osteoblastic lineage and
immune cells, and is able to link to the osteoclast surface
receptor, RANK, stimulating bone resorption through osteoclas-
togenesis and multinucleated mature osteoclasts activation [2].
As the years progressed, it has become clearer that targeting the
RANK–RANKL interaction could be of great relevance in the
treatment of diseases characterised by increased osteoclast acti-
vation, including osteoporosis and bone metastases. This led,
within a few years, to preclinical and clinical development of
denosumab, a fully humanised monoclonal IgG2 antibody
targeting RANKL.
Denosumab has been shown to reduce vertebral, hip, and non-
vertebral fracture risk in postmenopausal women, and to be
effective in delaying skeletal-related events in bone metastatic
solid cancers and multiple myeloma [3]. In addition to this effort
in ﬁrst elucidating and then targeting the RANK–RANKL axis in
the metastatic setting, considerable data were collected. This led
to a more complex and comprehensive view concerning the
abrogation of this pathway in cancer.
It has been demonstrated that RANKL plays a role in mammary
tumourigenesis. It acts as a major paracrine effector for the
mitogenic action of progesterone in mouse mammary epithelium
as well modulating oestrogen-dependent expansion and regen-
erative potential of mammary stem cells [4,5]. Moreover RANK
overexpressing transgenic mice showed a higher incidence of
breast cancer after multiparity or medroxyprogesterone acetate
treatment, whereas RANK silenced trangenic mice [4] or mice
treated with recombinant osteoprotegerin, [5] had decreased
incidence and delayed onset of tumourigenesis in these systems.
Murine model experiments even demonstrated that RANKL is
able to act as chemo- attractant and as pro-migratory factor in
RANK-expressing breast and prostate cancer cell lines. Moreover,
RANKL inhibition has been demonstrated to reduce bone lesions
and tumour burden in vivo in melanoma model of bone
metastasis [6].
All this evidence is, at least in part, conﬁrmed by exploration in
human samples where RANK expression level in the primary
tumour correlates with the occurrence of bone metastases, and
RANK-expressing cancer could be found in up to 80% of bone74/$ - see front matter & 2012 Elsevier GmbH. This is an open access article un
x.doi.org/10.1016/j.jbo.2012.11.001metastases originated from solid tumour [7,8]. However, a direct
pro-metastastic mechanism may not be responsible for the
supposed pro-tumoural role of RANK–RANKL pathway.
Currently the best described model is known as the ‘‘bone
vicious circle’’. In this model, RANK enables cancer cells to migrate
to bone to where RANKL is abundantly expressed by osteoblasts.
Some tumour cells may directly express RANKL, whereas others
further enhance RANKL expression by cell-to-cell contact of
tumour cells with osteoblastic cells. This leads cancer cells to enter
the vicious circle where they stimulate osteoclasts that express
RANK. Bone degradation by osteoclasts creates further space for
expansive tumour growth within the bone microenvironment and
releases a variety of growth factors and cytokines stored in the
bone matrix, including parathyroid hormone-related peptide
(PTHrP), IL-6, and transforming growth factor (TGF)-b, that boost
even further the proliferation of cancer cells [9].
Recently, it has been shown that dendridic cells (DCs) also
express RANK, and therefore can be stimulated by RANKL. RANKL-
stimulated DCs respond by up-regulation of co-stimulatory mole-
cules CD86, CD205 and cytokines such as TNF-a, IL-6, and IL-10
leading to CD4þ25þ T-regs (Foxp3þ) expansion and subsequent
local and systemic immunosuppression [10]. Intriguingly, in the
in-vivo breast cancer Her2þ model, RANK expression on tumour
cells has clearly been shown to enhance metastatic spread and
this phenomenon was strictly dependent on the presence of
FoxP3þ T-reg cells most important function, according to this
model, appeared to be as the major source of RANKL in cancer
microenvironment [11]. Furthermore, DCs from bone marrow
with metastatic prostate cancer selectively and highly express
RANK, while blockade of RANK/RANKL signalling pathway
disables the effects of DC-mediated T-reg-cell expansion and,
consequently, delays tumour growth in murine models [12].
Thus, according to the data in the literature, it is possible to
hypothesise the existence of an unknown ‘‘immune vicious circle’’
where RANKL produced by cancer cells or mesenchymal cells
(in response to factor secreted by cancer cells) could stimulate
DCs leading, in turn, to FoxP3þ T-reg cell expansion that in
turn produces further RANKL. The ﬁnal effect of this positive
feedback loop could be to enhance tumour invasiveness
through an increase of RANK activation in cancer cells as well
immune evasion properties through the increase in T-reg
activity and the well-known, adverse effects of FoxP3þ lymphocytes
in cancer [13].
Recently, denosumab demonstrated a signiﬁcant delay in the
onset of detectable bone lesions in men with castration resistant
prostate cancer compared to placebo [14]. This could indicate some
kind of efﬁcacy of the compound as anticancer agent andder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cancer progression. Currently, we are still far from fully under-
standing what really happens when disrupting the RANK/RANKL
axis in the ‘‘real world’’ and at the same time we do not know
which patients could beneﬁt from this approach over and above
the effects of denosumab as an anti-resorptive agent. Given the
decrease in tumourigenesis observed in mice treated with RANKL
blocking agents, we can speculate that denosumab may have a role
in breast cancer prevention as well as in reducing tumour relapse
after surgery. Finally, it has been demonstrated that tumour-
inﬁltrating FoxP3þ lymphocytes and RANK expression by tumour
cells are factors which limit the efﬁcacy of neoadjuvant treatments
in breast cancer [15,16]. These results suggest that the use of
denosumab in this particular setting might provide additional
beneﬁts to the patients. Elucidating these mechanisms more
clearly will be an exciting challenge for translational research in
bone oncology and could provide the opportunity to exploit RANK
inhibition strategies both within and beyond the bone.
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